Beyond K-pop and K-food, K-biologics is set to increase in popularity. According to Reports, Korea’s “bio fever” is being spurred on by the domestic development of biosimilars by firms such as Celltrion, Samsung Bioepis, LG Chem, GC Green Cross, Chong Kun Dang, CJ Healthcare, and Dong-A ST.
Celltrion is the world’s first to get approval for a biosimilar therapy with Remsima (infliximab) in Europe. Recent earnings report shows its sales accounting for 52 percent of first- quarter company’s sales in 2018. Together with the biosimilars for Herceptin and Rituxan, these biologics are seeing strong demand in the European Union (EU).
Samsung Bioepis also has four biosimilars in the EU - Benepali, Flixabi, Imraldi, and Ontruzant. The latter is currently fighting for market share with Celltrion’s Herzuma in Europe.
In Dec. 2018, Chong Kun Dang received approval for its biosimilar for the Novel erythropoiesis stimulating protein (NESP) while Dong-A ST together with Japan’s Meiji Holdings as well as CJ Healthcare with YL Biologics are in pursuit with their own NESP biosimilar.
Beyond Biosimilars, the development of better expression systems and modular & flexible manufacturing facilities including single use disposables have moved the Korean market towards higher yield and productivity gains. The key growth drivers of the biologics industry in Korea are new cell culture techniques, fast-track GMP facilities, flexible and continuous manufacturing.
Building on this momentum, the 8th Annual Biologics Manufacturing Korea 2019 (29 – 30 May | Seoul, South Korea) conference will accelerate collaboration and development with custom made focused sessions connecting regional and global pharmaceutical networks. You will witness 30 biomanufacturing key opinion leaders and 200+ attendees working along the biomanufacturing value chain. Exhibitors range from bioprocessing experts to consultants in engineering biomanufacturing facilities with more than 100 professional delegates.
Recently, Samsung Biologics headquartered in Korea added its third manufacturing facility to become the world’s largest biologics contract manufacturing organization (CMO) with a total production capacity of 360,000 litres. A pre-conference site tour to this new facility is available to pre-registered conference delegates on the afternoon of 28 May 2019.
Set the stage for Korea’s Bio-fever at the 8th Annual Biologics Manufacturing Korea 2019.
Download your Brochure here: https://www.imapac.com/business_conference/biologics-manufacturing-korea-2019/programme/.